Medications for Acute Coronary Syndromes

with primary every 4 weeks hyperlipidemia (including familial hypercholesterolemia) For patients not at target LDL-C levels, used alone or Initial dose for primary in combination with other hyperlipidemia: 140 mg lipid-lowering therapies subcutaneously every 2 (eg, statins, ezetimibe) for Evolocumab weeks or 420 mg the treatment of adults subcutaneously once with primary monthly hyperlipidemia (including familial hypercholesterolemia) Statins (HMG-CoA reductase inhibitors) Atorvastatin Fluvastatin Patients with CAD should Lovastatin Variable† (see be given maximally Dyslipidemia) Pravastatin tolerated statin dose Rosuvastatin Simvastatin Other medications Ivabradine 5 mg orally twice a day, Inhibits sinus node increased to 7.5 mg orally For symptomatic twice a day if needed treatment of chronic stable angina pectoris in patients with normal sinus rhythm who cannot take beta-blockers 9/17 Medication Dosage Use In combination with beta- blockers in patients inadequately controlled by beta-blocker alone and whose heart rate > 60 beats/minute 500 mg orally twice a day, Patients in whom anginal increased to 1000 mg symptoms continue Ranolazine orally twice a day as despite treatment with needed other antianginal drugs * Clinicians may use different combinations of medications depending on the type of coronary artery disease that is present. † Refer to the manufacturer's prescribing information or a
